Understanding PD-L1 CPS: Impact on Treatment Decisions in HER2+ Gastric Cancer

Experts discuss the PD-L1 combined positive score (CPS) and its influence on treatment decisions as well as the clinical significance of a high CPS in guiding the use of immune checkpoint inhibitors such as pembrolizumab in HER2-positive gastric cancer.

EP: 1.Robert’s Journey With HER2  Upper GI Cancer

EP: 2.Frontline Treatment and Molecular Testing in Upper GI Cancer: Precision-Guided Therapy

EP: 3.Reflex Testing in Upper GI Cancer: Optimizing Molecular Insights for Timely Treatment

EP: 4.The Role of Biomarkers for Immunotherapy Selection in Upper GI Cancer

EP: 5.Reassessing Biomarkers: Guiding Second-Line Therapy in Upper GI Cancer

EP: 6.Navigating Prognosis and Treatment Goals in Upper GI Cancer: A Patient- and Family-Centered Approach

EP: 7.Megan’s Journey With HER2+ Upper GI Cancer

Now Viewing

EP: 8.Understanding PD-L1 CPS: Impact on Treatment Decisions in HER2+ Gastric Cancer

Video content above is prompted by the following:

• Please explain what a PD-L1 CPS is, and how does it influence treatment decisions?
• What is the clinical significance of a high CPS in guiding the use of immune checkpoint inhibitors such as pembrolizumab in HER2-positive gastric cancer?

Recent Videos